Is Wegovy better than Saxenda for weight loss?

In the one trial that tested both in the same people, clearly yes. STEP 8 randomised 338 adults with overweight or obesity and without diabetes to once-weekly semaglutide 2.4 mg or once-daily liraglutide 3.0 mg for 68 weeks and reported a mean weight change of -15.8% with semaglutide against -6.4% with liraglutide — a difference of 9.4 percentage points, with pooled placebo at −1.9%. Two caveats belong with it: the active-versus-active comparison was open-label, and Novo Nordisk funded it. That second point is less damaging than usual, because Novo Nordisk markets both drugs and had a product on each side of the result.

What is the 16-week rule on Saxenda?

It is a labelled instruction to stop the drug if it has not worked, and Wegovy has no equivalent. Saxenda's section 2.2 reads: "Evaluate the change in body weight 16 weeks after initiating SAXENDA and discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment." For an adolescent the same section sets a different check — a 1% reduction in BMI after 12 weeks on the maintenance dose. Four per cent of a 100 kg starting weight is 4 kg by month four. If you are on Saxenda and nobody has weighed you against that threshold, it is a reasonable thing to raise.

How many milligrams of Wegovy equal 3 mg of Saxenda?

No number answers that, and anyone who offers one is inventing it. Liraglutide and semaglutide are different molecules with different half-lives and different dosing intervals, and no FDA label, clinical guideline or published trial states a milligram equivalence between them. The dose ceilings — 3 mg daily and 2.4 mg weekly, with 7.2 mg above it — are each the top of their own ladder and mean nothing when divided into one another. If you are switching, the new drug starts at its own labelled starting dose and climbs its own ladder; nothing about the old dose carries across, and both labels advise against running two GLP-1 receptor agonists at once.

Does Saxenda cause more side effects because it is daily?

Not according to the trial that tested both. In STEP 8, gastrointestinal adverse events were reported by 82.7% of the liraglutide arm and 84.1% of the semaglutide arm — 1.4 points apart, in the same trial, in the same population, which is as close to a clean comparison as this drug class offers. What did differ is who stayed: 27.6% of the liraglutide group discontinued treatment for any reason against 13.5% on semaglutide, roughly double. The trial does not say why, and a daily injection, a weaker result and a four-week rather than sixteen-week escalation are all plausible contributors it cannot separate.

Is there a generic for either of them?

For liraglutide, yes; for semaglutide, no. The CMS NADAC file dated 2026-09-16 prices a generic liraglutide 5-pak alongside branded Saxenda, and at the 3 mg maintenance dose a month is $725 against $1,325 for the brand. There is no generic semaglutide of any kind in that file, so Wegovy is $1,415 a month at 2.4 mg and $1,412 at 7.2 mg with no cheaper labelled route. These are all NADAC figures — what retail pharmacies reported paying on invoice — and none of them is a price you can walk in and pay.

What happens if I miss a few days of Saxenda?

More than three days and its label restarts you from the beginning. Section 2.1: "If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment." That puts you 5 weeks from the full dose again. Wegovy's rule is far gentler: if the next scheduled dose is more than two days away, take the missed one as soon as possible, otherwise skip it and carry on. For anyone who travels, works shifts, or has ever had a pharmacy run out of stock, that difference is not a footnote.

Head to head

Saxenda vs Wegovy

Both are Novo Nordisk weight-management injections and a real head-to-head trial compared them. The difference almost nobody mentions is that one label tells your prescriber when to stop.

Reviewed September 2026

The short answer

For weight, there is a head-to-head trial and it favours Wegovy by a wide margin. STEP 8 randomised 338 adults with overweight or obesity and without diabetes to once-weekly semaglutide 2.4 mg or once-daily liraglutide 3.0 mg for 68 weeks: 15.8% of body weight against 6.4%, a difference of 9.4 percentage points. One trial, one population, one protocol — which is why this page does not need to hold two separate trials up against each other.

The caveat is unusual and worth stating plainly. The semaglutide-versus-liraglutide comparison was open-label rather than blinded, and the trial was funded by Novo Nordisk — who make both drugs. The usual objection to a manufacturer-funded head-to-head does not apply in its normal form when the funder also owns the arm that lost.

The difference the labels themselves make is not about how much you lose but about when you stop. Saxenda's section 2.2 instructs the prescriber to evaluate weight at 16 weeks and to discontinue if the patient has not lost at least 4% of baseline body weight. Nothing of the kind appears anywhere in the Wegovy label. One drug has a labelled futility check and the other does not.

Everything else follows from daily against weekly. Saxenda is 365 injections a year from an 18 mg multi-dose pen you dial, reaching its 3 mg maintenance dose in 5 weeks; Wegovy is 52 injections a year from single-dose pens, reaching 2.4 mg at week 17. Miss three days of Saxenda and its label sends you back to 0.6 mg and up the whole ladder again; Wegovy has no such rule.

3 of 15 dimensions are materially the same. They are marked below rather than dressed up as differences.

Saxenda

liraglutide 3 mg · generic liraglutide

Once-daily liraglutide, 3 mg, in a 3 mL multi-dose pen — the older of the two, and the only one in this pair with an approved generic.

Dosing protocol →

Wegovy

semaglutide 2.4 mg · Wegovy HD 7.2 mg · Wegovy tablets 25 mg

Once-weekly semaglutide in single-dose pens, with two further indications the other label does not carry and a 7.2 mg high dose above maintenance.

Dosing protocol →

Side by side

Every row carries how well supported it is. A claim that only reflects common practice is labelled as such rather than presented as fact.

Dimension	Saxenda	Wegovy	Basis
Head-to-head weight result	6.4% of body weight at week 68	15.8% of body weight at week 68	literatureSTEP 8, 338 adults with overweight or obesity and without diabetes, randomised to liraglutide 3.0 mg daily or semaglutide 2.4 mg weekly. Open-label for this comparison; funded by Novo Nordisk, who make both. This is the only figure on this page that ranks the two, and it is a real comparison rather than an arithmetic one.
Labelled stop rule	Yes — evaluate at 16 weeks, discontinue if less than 4% of baseline body weight has been lost	None	labelSaxenda, section 2.2, verbatim: "discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment." No equivalent sentence exists in the Wegovy label; its only discontinuation instruction in section 5 concerns hypersensitivity.
Molecule and dosing frequency	Liraglutide, once daily — 365 injections a year	Semaglutide, once weekly — 52 injections a year	labelBoth are GLP-1 receptor agonists and neither touches a second receptor. Seven times the injections is the whole practical difference, and both labels allow any time of day without regard to meals.
Recommended dose	3 mg daily — "lower dosages are for titration only"	2.4 mg weekly, with 7.2 mg available above it	labelThe milligram figures are not comparable. Liraglutide and semaglutide are different molecules, no label, trial or guideline states a potency ratio between them, and nothing on this page converts one into the other.
Escalation ladder	0.6 → 1.2 → 1.8 → 2.4 → 3 mg, one week per step — 3 mg from week 5	0.25 → 0.5 → 1 → 1.7 → 2.4 mg, 4 weeks per step — 2.4 mg from week 17, 7.2 mg from week 21	labelBoth ladders are printed as tables in section 2.2 of their labels and both are computed here from those tables rather than retyped. Saxenda is at its full dose in 5 weeks; Wegovy takes 17 weeks to maintenance and 21 to the top of the range.
Missing doses	More than 3 days away and the label restarts you at 0.6 mg, back through the whole escalation table	If the next dose is more than 2 days away, take the missed dose as soon as possible; otherwise skip it	labelThe harshest asymmetry on either label for anyone whose life is not regular. A holiday, a hospital stay or a lost pen puts a Saxenda patient back at the bottom of the ladder and 5 weeks from full dose. Wegovy simply resumes.
Other approved indications	None — weight management only	Cardiovascular risk reduction in established CV disease with obesity or overweight; noncirrhotic MASH with F2–F3 fibrosis	labelBoth labels also cover adolescents aged 12 and over, but Saxenda adds a weight criterion there that Wegovy does not: "body weight greater than 60 kg and obesity". Neither section 1 states any BMI threshold in kg/m²; the BMI numbers people quote are trial enrolment criteria from section 14.
Device	Multi-dose pen you dial — 18 mg in 3 mL (6 mg/mL), 6 doses at 3 mg	Single-dose pen — one injection, one device, no dial and no leftover	labelA Saxenda pen at the full dose runs out after 6 days, well before the 30-day in-use limit, so a month is 5 pens. The concentration is the same 6 mg/mL in every approved liraglutide product, brand and generic alike.
Oral version	None — there is no approved oral liraglutide of any kind	Wegovy tablets, 25 mg once daily, on the same label	labelThe tablet is a separate ladder with a separate maximum and the label carries a two-way switch between it and the injection. Nothing equivalent exists for liraglutide.
Generic available	Yes — generic liraglutide is priced in the CMS NADAC file	No	literatureThis is the one dimension on which Saxenda wins outright and it is a market fact rather than a clinical one. A month of the generic is $725 against $1,325 for the brand at the same 3 mg dose.
Gastrointestinal adverse events, head to headsame	82.7% of participants	84.1% of participants	literatureFrom STEP 8, so this is the same trial in the same people — the rare case where two GLP-1 tolerability figures genuinely can be read across. They are 1.4 points apart. Whatever separates these drugs, it is not how many stomachs they upset.
Stopped treatment for any reason, head to head	27.6%	13.5%	literatureTwice as many people left the liraglutide arm, in a trial where gastrointestinal events were reported at the same rate in both. The trial does not explain the gap; the daily injection and the weaker result are both candidates and it does not separate them.
Boxed warningsame	Thyroid C-cell tumours; contraindicated in MTC or MEN 2 history	Thyroid C-cell tumours; contraindicated in MTC or MEN 2 history	labelThe same rodent finding and the same contraindication, word for word, on both labels. No part of this decision turns on it.
Combining with another GLP-1same	Not recommended with other liraglutide products or any other GLP-1 receptor agonist	Not recommended with other semaglutide products or any other GLP-1 receptor agonist	labelBoth state it as a Limitation of Use in section 1, in almost identical words. Switching between them therefore means stopping one, not overlapping.
What a pharmacy paid, per month	$1,325 brand, $725 generic — at 3 mg daily	$1,415 at 2.4 mg, $1,412 at 7.2 mg	literatureCMS NADAC, file dated 2026-09-16. Invoice cost to a retail pharmacy, not a cash price and not a copay. The generic is the only route in this comparison to a materially lower number, and it exists on one side only.

label: Stated on the FDA label
guideline: Clinical practice guideline
literature: Published literature
practice: Common practice, not documented

Which one

Choose Saxenda if

Cost is the binding constraint and you can get the generic. Generic liraglutide is the cheapest labelled weight-management injection in this comparison by a wide margin, and semaglutide has no generic at any price.
You have tried semaglutide and could not tolerate it, or it is unavailable. A different molecule is a real option in a way a different dose of the same one is not.
A daily routine suits you better than a weekly one. Some people find a small daily action easier to keep than a weekly appointment with themselves.
You want the label that tells you when it is not working. The 16-week, 4% check is a genuine safeguard against spending a year and several thousand dollars on a drug that was never going to help you.

Choose Wegovy if

Weight reduction is the goal and you have a free choice. STEP 8 is a head-to-head in the population you are in, and it favours semaglutide by 9.4 percentage points.
You have established cardiovascular disease with obesity or overweight, or noncirrhotic MASH with F2–F3 fibrosis. Both are Wegovy indications and neither is on the Saxenda label.
Your life is not regular. Missing three days of Saxenda sends you back to 0.6 mg and up the whole ladder; missing a Wegovy dose costs you nothing but the dose.
You would rather take a tablet eventually. Wegovy tablets exist at 25 mg daily with a labelled switch from the injection; there is no oral liraglutide anywhere.

The two things most likely to decide this are not on either label: what your plan covers and what your pharmacy can get. If you are choosing freely and the goal is weight, the head-to-head favours Wegovy. If you are paying close to acquisition cost, generic liraglutide is in a different price category from anything on the semaglutide side, and a drug you can afford for two years beats a better drug you can afford for four months. What this page will not do is turn 3 mg of liraglutide into a semaglutide dose or the other way round — they are different molecules and no potency ratio between them exists.

Frequently asked questions

Is Wegovy better than Saxenda for weight loss?: In the one trial that tested both in the same people, clearly yes. STEP 8 randomised 338 adults with overweight or obesity and without diabetes to once-weekly semaglutide 2.4 mg or once-daily liraglutide 3.0 mg for 68 weeks and reported a mean weight change of -15.8% with semaglutide against -6.4% with liraglutide — a difference of 9.4 percentage points, with pooled placebo at −1.9%. Two caveats belong with it: the active-versus-active comparison was open-label, and Novo Nordisk funded it. That second point is less damaging than usual, because Novo Nordisk markets both drugs and had a product on each side of the result.
What is the 16-week rule on Saxenda?: It is a labelled instruction to stop the drug if it has not worked, and Wegovy has no equivalent. Saxenda's section 2.2 reads: "Evaluate the change in body weight 16 weeks after initiating SAXENDA and discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment." For an adolescent the same section sets a different check — a 1% reduction in BMI after 12 weeks on the maintenance dose. Four per cent of a 100 kg starting weight is 4 kg by month four. If you are on Saxenda and nobody has weighed you against that threshold, it is a reasonable thing to raise.
How many milligrams of Wegovy equal 3 mg of Saxenda?: No number answers that, and anyone who offers one is inventing it. Liraglutide and semaglutide are different molecules with different half-lives and different dosing intervals, and no FDA label, clinical guideline or published trial states a milligram equivalence between them. The dose ceilings — 3 mg daily and 2.4 mg weekly, with 7.2 mg above it — are each the top of their own ladder and mean nothing when divided into one another. If you are switching, the new drug starts at its own labelled starting dose and climbs its own ladder; nothing about the old dose carries across, and both labels advise against running two GLP-1 receptor agonists at once.
Does Saxenda cause more side effects because it is daily?: Not according to the trial that tested both. In STEP 8, gastrointestinal adverse events were reported by 82.7% of the liraglutide arm and 84.1% of the semaglutide arm — 1.4 points apart, in the same trial, in the same population, which is as close to a clean comparison as this drug class offers. What did differ is who stayed: 27.6% of the liraglutide group discontinued treatment for any reason against 13.5% on semaglutide, roughly double. The trial does not say why, and a daily injection, a weaker result and a four-week rather than sixteen-week escalation are all plausible contributors it cannot separate.
Is there a generic for either of them?: For liraglutide, yes; for semaglutide, no. The CMS NADAC file dated 2026-09-16 prices a generic liraglutide 5-pak alongside branded Saxenda, and at the 3 mg maintenance dose a month is $725 against $1,325 for the brand. There is no generic semaglutide of any kind in that file, so Wegovy is $1,415 a month at 2.4 mg and $1,412 at 7.2 mg with no cheaper labelled route. These are all NADAC figures — what retail pharmacies reported paying on invoice — and none of them is a price you can walk in and pay.
What happens if I miss a few days of Saxenda?: More than three days and its label restarts you from the beginning. Section 2.1: "If more than 3 days have elapsed since the last SAXENDA dosage, reinitiate SAXENDA at 0.6 mg daily and follow the dosage escalation schedule in Table 1, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation of treatment." That puts you 5 weeks from the full dose again. Wegovy's rule is far gentler: if the next scheduled dose is more than two days away, take the missed one as soon as possible, otherwise skip it and carry on. For anyone who travels, works shifts, or has ever had a pharmacy run out of stock, that difference is not a footnote.

Sources

Next steps

Compare online weight-loss providersWhich platforms prescribe branded product, which dispense compounded, and what each charges.Medical weight loss, start to finishEligibility, the first six months, monitoring, and what happens if you stop.

Other comparisons

Educational reference, not medical advice. Which medication suits you is a decision for your prescriber.